All News

A new study has found that although the number of childhood cancer survivors is increasing, the majority of those to survive five or more years beyond diagnosis have at least one chronic health condition.

A partnership between the Pancreatic Cancer Action Network and Perthera, a self-described "concierge" for molecular diagnostic testing, is giving patients with this hard-to-treat cancer the ability to determine the best course of treatment.

The balance between living and living with cancer sometimes comes down to taking short medical breaks just to go on with your day.

It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.

Pretreated patients with recurrent ovarian cancer had a 2.5-month progression-free survival benefit when receiving fosbretabulin plus Avastin compared with Avastin alone; however, hypertension rates doubled.

Eligibility criteria set for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening, according to a new study.

The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease and thalassemia.

The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.

The reason breathing techniques are so powerful, is they can lower blood pressure, heart rate and ease tension on capillaries.

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage 3/4 ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not, according to an open-label phase 2 trial.

Stomach cancer non-profit organization hosts "Hereditary Diffuse Gastric Cancer: The past, the present, and hope for the future" event.

Diet is precisely where we have the opportunity to provide our bodies with cellular mediators of inflammation.

Cancer is a lonely, confusing experience. Finding others who have walked the path before can be an emotional lifesaver.

Three-time cancer survivor tells about her experience with second opinions.

Jean M. Weigert, head of breast imaging for the Hospital of Central Connecticut, discusses results of a study examining supplemental ultrasound screening in women with dense breast tissue.

Melissa Long knows first-hand what it is like to battle isolation and depression as a teenage cancer survivor.

Oncologist Don Dizon explains the advantages of intraperitoneal therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.

Elizabeth A. Mittendorf, associate professor of surgical oncology at The University of Texas MD Anderson Cancer Center, discusses the progress and potential of immunotherapy in breast cancer treatment.

The development of agents targeting the PD-1 immune checkpoint in the treatment of patients with advanced melanoma is progressing rapidly.

A trial comparing frontline Keytruda (pembrolizumab) with Yervoy (ipilimumab) for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints.

Anger is a common emotional response to being diagnosed with and treated for cancer. Openly expressing it can be a struggle.

Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.

A new study has found that a psychosocial telephone counseling intervention helps improve mood and quality of life in cervical cancer survivors.

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of Avastin and Lynparza, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines in its 20th annual edition.

Results of a follow up study have shown that when women were taught stress management techniques early in their breast cancer treatment, their mood and quality of life continued to improve up to 15 years later.

Breast cancer specialist Mark Pegram discusses recent breast cancer studies and what's to come for patients with HER2-positive breast cancer.

In the ring, it's not about whether you win or lose; it's about never staying down and never giving up.

Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.